Steam power: new device aims to zap prostate cancer without major side effects

NCT ID NCT05683691

Ongoing Disease control Sponsor: Francis Medical Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a device called Vanquish that uses water vapor (steam) to destroy prostate cancer tissue in men with intermediate-risk, localized prostate cancer. The goal is to control the cancer while avoiding common side effects like incontinence and impotence. About 400 men aged 50 and older are taking part across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: water vapor ablation (Vanquish System)
What this could lead to: If successful, this could offer a less invasive treatment option for intermediate-risk prostate cancer that controls the disease while reducing side effects like incontinence and impotence.
What could go wrong: This is an early-stage, single-arm study with no comparison group, so results may not be definitive. The treatment may not fully control the cancer, and risks like infection or urinary issues remain possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED INTERMEDIATE-RISK PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Carolina Urologic Research Center

Myrtle Beach, South Carolina, 29572, United States
Chesapeake Urology

Baltimore, Maryland, 21204, United States
Corewell Health / William Beaumont University Hospital

Royal Oak, Michigan, 48073, United States
Duke Cancer Institute

Durham, North Carolina, 27710, United States
Houston Methodist Hospital and Research Institute

Houston, Texas, 77030, United States
Johns Hopkins

Baltimore, Maryland, 21287, United States
Kasraeian Urology

Jacksonville, Florida, 32216, United States
Mayo Clinic- Phoenix

Phoenix, Arizona, 85054, United States
Mayo Clinic- Rochester

Rochester, Minnesota, 55905, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Memorial Care

Laguna Hills, California, 92653, United States
Michigan Institute of Urology

Troy, Michigan, 48084, United States
MidLantic Urology

Bala-Cynwyd, Pennsylvania, 19004, United States
Minnesota Urology

Woodbury, Minnesota, 55125, United States
NYU Langone Health

New York, New York, 10016, United States
Northwell Health- Lenox Hill Hospital

New York, New York, 11222, United States
The Urology Group

Cincinnati, Ohio, 45212, United States
The Urology Place

San Antonio, Texas, 78240, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Minnesota

Minneapolis, Minnesota, 55454, United States
University of Rochester

Rochester, New York, 14620, United States
University of Southern California

Los Angeles, California, 90089, United States
Urology Austin

Austin, Texas, 78745, United States
Urology of Virginia, PLLC

Virginia Beach, Virginia, 23462, United States
Wichita Urology

Wichita, Kansas, 67226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.